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The recently FDA-licensed anti-IgG gel test for pretransfusion antibody
detection requires crossover validation before implementation.  Six
hundred coded samples sent for routine pretransfusion tests were
used to compare GEL (ID-MTS, Ortho Diagnostic Systems Inc., Raritan,
NJ) with Löw and Messeter’s low-ionic-strength saline (LISS).  There
were 456 GEL–LISS–, 97 GEL+LISS+, 45 GEL–LISS+, and 2 GEL+LISS–
tests.  The 144 positive tests involved 157 antibodies; 67 of these (cold
auto, anti-M, -Le, etc.) were considered harmless with respect to trans-
fusion management.  GEL–LISS+ tests included seven samples con-
taining potentially significant antibodies (assumed from specificity):
anti-K(4), -Jka, -Fyb, and -S.  Two potentially significant antibodies (anti-
C and -D) were GEL+LISS–.  Sensitivity and specificity for potentially
significant antibodies were 92% and 96% for GEL, and 98% and 90%
for LISS, respectively.  The seven GEL–LISS+ samples associated with
potentially significant antibodies were from six patients.  Five of these
antibodies, all detected in immune-suppressed patients, reacted pre-
dominantly as agglutinins in LISS.  None of these seven antibodies
were detected reliably by polyethylene glycol and LISS-additive tube
methods.  In light of the immune status of the patients with GEL–LISS+
agglutinins with specificity normally considered potentially significant,
and because other valid methods did not detect these antibodies, their
clinical importance is questionable.  Excluding these questionable anti-
bodies, GEL has the same sensitivity and better specificity than LISS.
GEL is a valid method for pretransfusion antibody detection.
Immunohematology 1997;13:132–135.
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The gel test for detecting red blood cell (RBC) antigen-
antibody interactions has been utilized by blood group
serologists outside the United States since its first descrip-
tion in 1990 by Lapierre and colleagues.1 In 1994, Micro
Typing Systems, Inc. (Pompano Beach, FL), obtained
approval from the U.S. Food and Drug Administration to
manufacture an anti-IgG gel test (GEL) for detection of
unexpected antibodies.2 This product (ID-MTS GEL) is
now available in the United States through Ortho
Diagnostics Systems Inc. (Raritan, NJ).
There are reports of studies comparing the European
version of GEL (DiaMed AG, Morat, Switzerland) with
tube technologies utilized in Europe and Canada.3-5
However, there are no reports that compare ID-MTS GEL
with enhancement methods in use in transfusion services
within the United States.  Moreover, as with any new 
technology under the Clinical Laboratory Improvement
Act of 1988,6 GEL requires crossover validation before 
implementation.
In this report, we present serologic findings compar-
ing GEL to our routine antibody detection procedure
based on the LISS procedure of Löw and Messeter.7
Materials and Methods
An ID-Micro Typing System™ for performing anti-IgG
gel tests was provided courtesy of Ortho Diagnostics
Systems Inc.  Samples for GEL were predominantly from
EDTA-anticoagulated blood and were from patients on
whom routine pretransfusion tests had been performed
within the preceding 48 hours.  Samples were subjected
to GEL within 48 hours of collection.  Technologists per-
forming GEL were not privy to the findings by LISS.
Group O reagent CDe/CDe (R1R1) and cDE/cDE
(R2R2) RBCs were from Immucor, Inc. (Norcross, GA).
One of these RBC samples was always Jk(a+b–).  The
same lot number of reagent RBCs was used for both GEL
and LISS.
LISS tests were performed by incubating one volume
(ca. 0.1 mL) of 2% reagent RBCs in LISS (Immucor, Löw
and Messeter’s formulation7) with an equal volume of
patient’s serum.  The reactants were not warmed to 37°C
before mixing.  Incubation was for 10 minutes at 37°C,
after which the tests were centrifuged and examined for
agglutination and hemolysis. The RBCs were then washed
x 4 with saline before testing with polyclonal (rabbit) anti-
IgG (Ortho).  Reactions were read macroscopically with
the aid of an illuminated concave mirror and graded as
described previously.8 All negative antiglobulin tests
were verified with IgG-coated RBCs (Immucor).
GEL tests were set up and graded as recommended by
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the manufacturer.  Briefly, 50 μL of 0.8% reagent RBCs
suspended in a low-ionic-strength diluent were mixed
with 25 μL of plasma.  After a 15–minute incubation at
37°C, the RBCs were centrifuged through a gel column
containing anti-IgG.  In our laboratory, reactions in GEL
were read utilizing an illuminated view box; doubtful
reactions were evaluated using a handheld magnification
lens.
Results by GEL were compared with those by LISS.
Discrepancies were evaluated by repeat testing by both
methods, using both serum and EDTA plasma, as avail-
able.  When apparent significant antibodies were missed
by GEL, additional testing was undertaken using multiple
LISS additives and polyethylene glycol (PEG).9 Statistical
analysis of test data were performed as described by
Annesley.10
Results
Results of GEL and LISS tests for unexpected antibod-
ies on 600 samples are shown in Table 1.  There were 
456 GEL–LISS–, 97 GEL+LISS+, 45 GEL–LISS+, and 2
GEL+LISS– samples.  The 144 reactive samples involved
90 antibodies of potential significance (presumed from
specificity) and 67 antibodies that were considered harm-
less with respect to transfusion of incompatible blood
(cold auto, Paraben®-dependent anti-Jka,11 -M, -Le, etc.)
LISS detected 66/67 harmless antibodies and 88/90 anti-
bodies of potential significance.  In contrast, GEL detect-
ed 22/67 harmless antibodies and 83/90 potentially
significant antibodies.  GEL did not detect seven poten-
tially significant antibodies in six patients (anti-K(4), -Jka,
-Fyb, and -S), while LISS failed to detect two Rh antibod-
ies (anti-C and -D).
Specific details of our findings on the eight patients
whose serum contained potentially significant antibodies
that yielded nonconcordant results are summarized in
Table 2.  The seven presumed potentially significant
GEL–LISS+ antibodies involved five that reacted predom-
inantly as direct agglutinins in LISS.  All but one of the
seven antibodies were from patients who were immune
suppressed by disease or medication; the exception was
the anti-S, which was from a 14-year-old boy who had
never been transfused.
Also shown in Table 2 are specific details on two sam-
ples containing potentially significant Rh antibodies that
were missed by LISS.  It is of note that the anti-D was from
a patient alleged to have anti-E by an outside hospital.  In
routine antibody identification studies, which included
both LISS and ficin-antiglobulin techniques, no Rh anti-
body activity was observed but anti-D was clearly demon-
strable by GEL.
Table 3 shows the results of additional tests performed
on the six patients with GEL–LISS+ antibodies of poten-
tial significance.  Of relevance is the finding that some
widely used commercially available LISS-additives, an in-
house LISS preparation based on the formulation of Löw
and Messeter,7 and PEG tube tests9 did not reliably detect
these antibodies.
Table 4 shows the results of predictive value analysis of
the data.  GEL was superior to LISS in terms of specificity
and therefore has greater test efficiency.  LISS was supe-
rior to GEL in its ability to detect antibodies of specifici-
ties that are considered potentially significant with
respect to transfusion of incompatible blood (but see
Discussion).
Table 1. Results of comparative study between GEL and LISS
Significance* Reaction Samples Antibodies Specificity
GEL–LISS– 456
Harmless GEL+LISS+ 20† 21
GEL–LISS+ 38 45 cold auto (18), M(8), 
Le(8), NOID‡(5†), 





GEL+LISS– 1 1 auto-Pr
TOTAL 59 67
Significant GEL+LISS+ 77† 81
GEL–LISS+ 7 7 K(4), Jka, S, Fyb
GEL+LISS– 1 2 C, D†
Total 85 90
Grand Total 600 157
* Presumed significance based on specificity and derived from clinical 
experience, with respect to transfusion of incompatible blood
† One GEL+LISS+ sample contained a GEL+LISS– anti–D and an unidentified
GEL–LISS+ antibody
‡ Not identified; reaction pattern inconsistent with single or multiple 
alloantibody specificities
§ An additional example of anti-Jka dependent upon the presence of
Paraben®, an anti-fungicide used in the commercial preparation of LISS11
Table 2. Discrepancies between GEL and LISS involving antibodies of 
presumed potential significance
Test            LISS*         
red blood
Anti- cells 37°C IgG GEL* Patient’s medical history†
Jka Jk(a+b–) 1+ 0 0 allogeneic bone marrow 
transplant
K‡ K+k+ 1+ 0 0 chronic myelogenous 
leukemia
S S+s+ 0 1+ 0 craniotomy, 
not transfused
K K+k– 2+ 1+ 0 liver transplant
K K+k– 1+ 0 0 chronic renal failure§
Fyb Fy(a–b+) 0 + 0 lung transplant
C CDe/CDe 0 0 1+ chronic renal failure
D cDE/cDE 0 0 1+ posttransfusion hepatitis
* Reactions graded as described in the text
† All patients multiply transfused except as indicated
‡ Two samples tested on different occasions yielded similar results
§ Patient also had C. difficile colitis
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Discussion
This study has shown that the sensitivity and specifici-
ty of GEL is satisfactory for routine pretransfusion and
perinatal antibody detection.  Moreover, according to the
results of test efficiency calculations, which indicate how
many times a test yields the right answer, GEL is superior
to LISS.
LISS detected seven antibodies (in six patients) of
potential significance (assumed from specificity) that
were not detected by GEL.  In evaluating the relevance of
this observation, the following should be considered.
First, there are no published reports of hemolytic trans-
fusion reactions attributed to the widespread use of those
LISS-additive methods that failed to detect these agglu-
tinins (see Table 3).  Second, there are no published
reports of hemolytic transfusion reactions associated with
the fact that the widely utilized PEG technique9 does not
include a reading for agglutination after 37°C incubation.
Third, the absence of reports of hemolytic transfusion
reactions following the widespread implementation of
GEL by transfusion services outside the United States also
supports the contention that these antibodies are not clin-
ically relevant.  Indeed, subsequent to this study and in
light of our previously published data,12 we have elimi-
nated the 37°C reading from our routine LISS antibody
detection procedure.  This measure improves the pre-
dictive value of a positive LISS test from 57% to 76% (vs.
79% for GEL) but is not associated with an increase in the
number of observed hemolytic transfusion reactions.13
Early in this evaluation, we found accuracy of RBC con-
centration and use of plasma rather than serum to be
advantageous in avoiding “toplines,” thin lines of unag-
glutinated RBCs that appear on top of the gel column
after centrifugation.  In addition, it was noted that agglu-
tinins (anti-I, -M, etc.) and rouleaux may yield unique reac-
tion patterns by GEL (mixed-cell, toplines, or a diffuse ver-
tical column of RBCs within the gel).  In our experience,
these unusual reactions as well as some weakly reactive
antibodies were more readily discernible using an illumi-
nated view box and magnification lens; how-ever, rec-
ommendations for or against the use of either of these
optical aids are not included in the manufacturer’s pack-
age insert.
As with any new technology, in addition to the sero-
logic evaluation (validation) of GEL for antibody detec-
tion, other factors to consider prior to implementation
include (1) validation of antibody identification and other
antiglobulin test procedures; (2) work process redesign
to facilitate efficient setup of GEL antibody detection with
ABO/Rh tube testing or to perform these tests indepen-
dently; (3) costs per test, including personnel time and
costs for commodities; (4) the ability to batch tests in
order to maximize the cost-effectiveness of GEL; (5) cur-
rent good manufacturing and compliance issues relative
to CLIA '88;6 (6) staff training and competency assess-
ment; and, (7) revisions to standard operating proce-
dures.  These issues will be addressed in subsequent
reports.  From data presented in this present study, we
conclude that GEL is a valid method for pretransfusion
antibody detection.
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Table 3. Results of additional testing on patients with presumed potentially significant antibodies missed by GEL* using an IgG antihuman globulin test (AHG)
                                            LISS-additives†                                        
L1 L2 L3 L4§
PEG‡
Anti- AHG ll 37°C AHG 37°C AHG 37°C AHG 37°C AHG Specificity¶
Jka 0 4+ 0 0 0 0 0 0 0 not confirmed**
K†† 0 4+ 1+ 0 0 0 0 0 0 confirmed
S 0 0 0
K 0 3+ 0 0 0 confirmed
K 0 3+ 0 confirmed
Fyb 2+ 0 0 0 0
*    Majority of testing performed elsewhere
†   Three commercially available LISS-additive reagents
‡   In-house polyethylene glycol solution (PEG)9
§   In-house LISS solution based on the formulation of Löw and Messeter7
ll Antihuman globulin test
¶   Antibody specificity confirmed/not confirmed in subsequently performed antibody identification tests using the most reactive method
**  Reacted 4+ at 37°C with one Jk(a+b–) RBC sample using LISS-additive #1; a Jk(a+b+) sample was nonreactive; antibody was nonreactive in subsequent testing
†† Two samples tested on different occasions; second sample not submitted for additional testing
Gel test validation
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_______________ x 100 _______________ x 100 = 95% _______________ x 100 = 90%
TP+FP+FN+TN 83+21+7+494 88+56+2+457
* Sensitivity and PV+ calculations based on reactions of antibodies  encountered during study (see Table 1)
† Specificity, PV–, and efficiency calculation determined from numbers of reactive and nonreactive samples (see Table 1)
‡ PV+ = predictive value of a positive reaction; PV– = predictive value of a negative reaction
